Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2005 1
2014 1
2015 1
2019 1
2021 2
2022 1
2023 1
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
CD3-CD8 immune score associated with a clinical score stratifies PDAC prognosis regardless of adjuvant or neoadjuvant chemotherapy.
Schoumacher C, Derangère V, Gaudillière-Le Dain G, Huppe T, Rageot D, Ilie A, Vienot A, Borg C, Monnien F, Bibeau F, Truntzer C, Ghiringhelli F; CGE-Pancreas investigators. Schoumacher C, et al. Among authors: rageot d. Oncoimmunology. 2023 Dec 21;13(1):2294563. doi: 10.1080/2162402X.2023.2294563. eCollection 2024. Oncoimmunology. 2023. PMID: 38169969 Free PMC article.
Machine learning evaluation of immune infiltrate through digital tumour score allows prediction of survival outcome in a pooled analysis of three international stage III colon cancer cohorts.
Lecuelle J, Truntzer C, Basile D, Laghi L, Greco L, Ilie A, Rageot D, Emile JF, Bibeau F, Taïeb J, Derangere V, Lepage C, Ghiringhelli F. Lecuelle J, et al. Among authors: rageot d. EBioMedicine. 2024 Jul;105:105207. doi: 10.1016/j.ebiom.2024.105207. Epub 2024 Jun 15. EBioMedicine. 2024. PMID: 38880067 Free PMC article.
Follicular helper-T cells restore CD8+-dependent antitumor immunity and anti-PD-L1/PD-1 efficacy.
Niogret J, Berger H, Rebe C, Mary R, Ballot E, Truntzer C, Thibaudin M, Derangère V, Hibos C, Hampe L, Rageot D, Accogli T, Joubert P, Routy B, Harker J, Vegran F, Ghiringhelli F, Chalmin F. Niogret J, et al. Among authors: rageot d. J Immunother Cancer. 2021 Jun;9(6):e002157. doi: 10.1136/jitc-2020-002157. J Immunother Cancer. 2021. PMID: 34103351 Free PMC article.
Combination of CDX2 H-score quantitative analysis with CD3 AI-guided analysis identifies patients with a good prognosis only in stage III colon cancer.
Derangère V, Lecuelle J, Lepage C, Aoulad-Ben Salem O, Allatessem BM, Ilie A, Bouché O, Phelip JM, Baconnier M, Pezet D, Sebbagh V, Terrebonne E, Bouard G, Jooste V, Bouvier AM, Molimard C, Monnien F, Gonzalez D, Le Malicot K, Rageot D, Truntzer C, Bibeau F, Ghiringhelli F; PRODIGE 13 investigators and collaborators. Derangère V, et al. Among authors: rageot d. Eur J Cancer. 2022 Sep;172:221-230. doi: 10.1016/j.ejca.2022.05.040. Epub 2022 Jul 1. Eur J Cancer. 2022. PMID: 35785606 Free article.
Case report: Immune response characterization of a pseudoprogression in a PD-L1-negative, TMB-low, KEAP1/STK11 co-mutated metastatic NSCLC.
Roussot N, Thibaudin M, Fumet JD, Daumoine S, Hampe L, Rébé C, Limagne E, Lagrange A, Herreros V, Lecuelle J, Mananet H, Ilie A, Rageot D, Boidot R, Goussot V, Comte A, Jacob P, Beltjens F, Bergeron A, Charon-Barra C, Arnould L, Derangère V, Ladoire S, Truntzer C, Ghiringhelli F. Roussot N, et al. Among authors: rageot d. Front Immunol. 2024 Aug 7;15:1437961. doi: 10.3389/fimmu.2024.1437961. eCollection 2024. Front Immunol. 2024. PMID: 39170614 Free PMC article.
12 results